Objective: Interaction of CA19-9 with E-selectin is involved in initiation of hematogenous metastases. We investigated whether serum concentrations of E-selectin and CA19-9 are good predictors of hematogenous metastases and prognosis in colorectal cancer. Methods: Pre-operative serum samples were obtained from 152 patients with colorectal cancer, and from 28 healthy volunteers. Correlation between serum E-selectin and CA19-9 was studied in terms of clinically detected hematogenous metastases and prognosis of patients.
INTRODUCTION
E-selectin, which was originally discovered as a homing receptor named endothelial leukocyte adhesion molecule 1, is an adhesion molecule that is expressed on cytokine-activated endothelial cells (1) . It was discovered originally as a homing receptor, which mediates the migration of neutrophils and monocytes to inflammatory foci (1) . It is well known that E-selectin binds as a ligand to specific carbohydrate antigens, such as sialyl Lewis X and sialyl Lewis a (carbohydrate antigen 19-9; CA19-9), which previously have been regarded as tumor marker 0 (2, 3) . One of the crucial steps in the development of hematogenous metastases is thought to be the attachment of malignant cells to endothelial cells. Also, it is thought that interaction of carbohydrate antigens with E-selectin is involved in initiating hematogenous metastases. CA19-9 has been used as a tumor marker of colorectal cancer in clinical practice (4 -6) , usually accompanied with CEA (7 -10). Several authors have described the prognostic significance of CA19-9 (5, 7, 11, 12) . Some studies have indicated the possible usefulness of CA19-9 in monitoring recurrence (13 -15) , whereas others have shown contradictory results (16, 17) . On the other hand, soluble forms of E-selectin have been detected in the serum of cancer patients (18) . Furthermore, some studies have indicated that these soluble forms of E-selectin are of prognostic and diagnostic importance in colorectal cancer and other malignancies (19, 20) . However, there is controversy in the literature regarding how soluble forms of E-selectin may be linked to life expectancy and specific sites of metastases (21, 22) . All of these studies in colorectal cancer have employed small numbers of cases (at most, 60 patients), whereas, more than 150 patients were analysed in the present study.
The purpose of the present study was to investigate whether serum concentrations of E-selectin and CA19-9 in peripheral venous blood are good predictors of hematogenous permeation of tumor cells and life expectancy in patients with colorectal cancer. We also studied correlation between serum concentrations of E-selectin and CA19-9 in terms of hematogenous metastases and prognosis of patients with colorectal cancer. Prognosis was examined according to the categorization by serum concentrations of E-selectin and CA19-9.
PATIENTS AND METHODS

PATIENTS
Serum samples were obtained pre-operatively from 152 patients (95 male and 57 female, average age 64.6 years, age range 41 -87 years) with colorectal cancer who underwent surgery at the Department of Surgery, Fujita Health University Hospital, Japan between August 2001 and December 2008, and from 28 healthy volunteers (26 male and 12 female, average age 41.6 years, age range 23 -83 years). To avoid the influence of inflammation, samples that were positive for C-reactive protein, or leucocytosis were excluded. Tumor staging was defined by at least two diagnostic methods including computed tomography (CT), ultrasound or magnetic resonance imaging at the time the blood was taken. Clinical and pathological findings were described following the Japanese classification of colorectal carcinoma (23) . In pathological staging, 17 cases were Dukes' A, 55 Dukes' B, 59 Dukes' C and 21 Dukes' D. Histologically, 88 cases were well-differentiated adenocarcinoma, 54 were moderately differentiated adenocarcinoma, 5 were poorly differentiated adenocarcinoma, 3 were mucinous carcinoma, 1 was signet ring carcinoma and 1 was squamous cell carcinoma. Oral 5-fluorouracil (5FU) derivatives were administrated for 12 months to patients with Dukes' B cancer. Bolus infusion of 5FU and leucovorin, or UFT and Uzel (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) were given for 6 months followed by administration of UFT for 6 months as adjuvant chemotherapy to patients with Dukes' C cancer. The 17 patients with metastasis were treated with the current standard therapy in Japan according to JSCCR guidelines 2009 for the treatment of colorectal cancer (24) . All patients were followed up at the outpatient clinic after hospital discharge. The median follow-up was 83.7 months (range 1.5 -102 months), and no patient was lost to follow-up. The follow-up was performed according to JSCCR guidelines 2009 for the treatment of colorectal cancer (24) . The follow-up system consisted of measurement of serum tumor markers every 3 months for the first 3 years and every 6 months for the next 2 years, hepatic imaging (US and/or CT) and chest CT every 6 months, pelvic CT for rectal cancer every year and colonoscopy every 1 -2 years for 5 years.
ASSAYS OF E-SELECTIN AND CA19-9
Blood samples were centrifuged for 15 min at 1000Âg. promptly to isolate the serum, and were stored at 2808C until assay. Serum E-selectin concentrations were measured using an ELISA kit for E-selectin (R&D Systems Inc. Human, Parameter ELISA Kit, Minneapolis, MN, USA). Antibody to human E-selectin conjugated to horseradish peroxidase in buffer was added to each well, which was precoated with a mouse monoclonal antibody to human E-selectin. Standards, E-selectin control and diluted samples were introduced into the wells to ensure mixing. Soluble E-selectin in the patient's serum bound to the coated antibody, while the second antibody bound to another epitope of E-selectin. After 1.5 h of incubation at room temperature, the unbound enzyme-conjugated anti-E-selectin was removed by washing, and tetramethylbenzidine was added to each well for colour development. Following 30 min incubation at room temperature, acid solution was added to each well to stop the reaction. The absorbance was measured at 450 nm by an ELISA reader (Molecular Devices Corporation, Sunnyvale, CA, USA). Serum concentrations of CA19-9 were determined at the clinical laboratory using ELISA kit (Fujirebio Inc., Tokyo, Japan).
All 152 cases were divided into four groups using the serum concentrations of CA19-9 and E-selectin: group I (94 cases), patients with low serum concentration of CA19-9 and low serum concentration of E-selectin; group II (27 cases), high CA19-9 and low E-selectin; group III (21 cases), low CA19-9 and high E-selectin; and group IV (10 cases), high serum concentrations of CA19-9 and E-selectin. The cutoff level was defined as 37 U/ml for serum CA19-9, and as 50 U/ml for serum E-selectin. The clinico-pathological stage and prognosis, including recurrence, were compared among these four groups.
STATISTICAL ANALYSIS
Statistical analysis was carried out using statistical software (StatView; Abacus, Tokyo, Japan). Results were expressed as mean + SD. The unpaired t-test or Mann -Whitney U-test was used for unpaired comparison. Categorical variables were analysed with the x 2 test or Fisher's exact probability test. Survival rates were calculated by the Kaplan -Meier method and compared by the log-rank test. Probability values of P , 0.05 were considered to be significant.
RESULTS
The average serum level of E-selectin before surgery was 38.2 + 21.0 U/ml in patients, and 30.7 + 19.2 U/ml in healthy volunteers. Serum levels of E-selectin in patients with colorectal cancer were significantly higher than in healthy volunteers (P ¼ 0.04). A high level of E-selectin was defined as .50 ng/ml (average þ standard deviation in healthy volunteers), and on that basis, 20.4% of all patients belonged to the high E-selectin group. The median serum level of CA19-9 was 14.8 U/ml (range 0.1 -3503 U/ml) in patients, and 11 U/ml (range 2.5 -52.1 U/ml) in healthy volunteers. Serum levels of CA19-9 in patients with colorectal cancer were significantly higher than in healthy volunteers (P ¼ 0.03). When the cutoff value of CA19-9 was set at 37 ng/ml, 24.3% of all patients belonged to the high CA19-9 group.
Comparisons of clinico-pathological factors according to the serum levels of CA19-9 and E-selectin are shown in Table 1 . The rates of T3 and T4 rectal cancer, lymph node metastasis greater than stage N2, Dukes' D cancer were significantly higher in the high CA19-9 group than in the low group. On the other hand, the rate of moderate to severe venous invasion was more in the high E-selectin group than in the low group. The sites of metastases according to the serum levels of CA19-9 and E-selectin are shown in Table 2 . Eight patients (21.6%) in the high CA19-9 group and seven (22.6%) in the high E-selectin group had liver metastasis. The frequency of liver metastasis was significantly greater in the high than the low CA19-9 group, and also greater in the high than the low E-selectin group.
The frequencies of curative surgery, recurrence rates and recurrence sites according to the serum levels of CA19-9 and E-selectin are shown in Table 3 . Curative surgery was performed in 26 patients (70.3%) in the high CA19-9 group, and in 104 (90.4%) in the low CA19-9 group. A significant difference was found in the frequency of curative surgery between the high and the low CA19-9 groups. In contrast, there was no significant difference in the frequency of recurrence between the high CA19-9group (19.2%) and the low CA19-9 group (18.3%). There was no significant difference in the frequency of curative surgery between the high E-selectin group (77.4%) and low E-selectin group (87.6%). There was also no significant difference in their frequency of recurrence between the high E-selectin group (20.8%) and low E-selectin group (17.9%).
The results of a cohort study on prognosis of patients according to the serum levels of CA19-9 and E-selectin are shown in Fig. 1 . Overall the 5-year survival rate was 63.0% in the high CA19-9 group, and 76.5% in the low CA19-9 group. Prognosis was significantly worse in the high than in the low CA19-9 group. There was no significant difference in the prognosis between the high E-selectin group (67.8%) and low E-selectin group (75.1%).
Clinico-pathological features that were considered to be related to prognosis were compared among the four groups with different serum levels of CA19-9 and E-selectin. The rates of Dukes' D cancer varied among the groups. Six patients (60.0%) in group IV had Dukes' D cancer. The rate of Dukes' D cancer was significantly higher in group IV than group II, both of which belong to the high CA19-9 group (Table 4) . However, there were no significant differences between groups II and I, and groups II and III in the frequency of Dukes' D cancer.
The sites of metastases according to the groups defined by serum levels of CA19-9 and E-selectin are shown in Table 5 . The frequency of liver metastasis was significantly greater in group IV than the other groups.
The frequencies of curative surgery, recurrence rates and recurrence sites according to the groups defined by serum levels of CA19-9 and E-selectin are shown in Table 6 . Curative surgery was performed in 84 patients (89.4%) in group I, 22 (81.5%) in group II, 20 (95.2%) in group III and four (40.0%) in group IV. Recurrence after curative surgery was found in 15 patients (17.9%) in group I, four (18.2%) in group II, four (20.0%) in group III and one (25.0%) in group IV. Significant differences were found in the frequency of curative surgery between groups IV and II (P ¼ 0.01). However, there were no significant differences between groups II and I, and groups II and III. There were no significant differences in the frequencies of recurrence after curative surgery among the four groups.
Overall 5-year survival rates were 79.7% in group I, 71.5% in group II, 76.8% in group III and 34.3% in group IV ( Fig. 2A and B) . Prognosis was significantly poorer in group IV than group II (P ¼ 0.02), which also belongs to the high CA19-9 group (Fig. 2B) , whereas there was no significant difference in prognosis between group I and group III, which belongs to the low CA19-9 group (Fig. 2A) . No difference was observed between groups II and the low CA19-9 group (group I and group III: 78.8%) (P ¼ 0.41).
DISCUSSION
E-selectin is expressed highly on endothelial cells treated with cytokines, such as interleukin-1 and tumor necrosis factor (1). The interaction of carbohydrate antigens, sialyl Lewis X and sialyl Lewis a (CA19-9), with E-selectin is involved in initiating hematogenous metastases (25, 26) . CA19-9 is used as a routine tumor marker for the diagnosis of many gastroenterological malignancies including colorectal cancer (3, 4) . The positive rate of CA19-9 has been reported to be very high (16.9 -35%) in colorectal cancer (8,9,12,27 ). Pre-operative elevation of CA19-9 was observed Venous invasion, and lymphatic invasion were described according to Japanese classification of colorectal carcinoma (29) ; LN, Lymph node. in 37 patients (24.3%) in the present study. The rate of high serum level of CA19-9 rose in each stage as clinical staging according to Dukes' classification was advanced. Increased serum levels of CA19-9 were considered to be a sign of tumor progression. A significant relationship between CA19-9 and nodal involvement has been reported by Nozoe et al. (10) Significant correlation between CA19-9 and hematogenous metastasis has been confirmed by Nakayama et al. (28) High serum level of CA19-9 is correlated significantly with liver metastasis (19) . Furthermore, it has been reported that high serum level of CA19-9 is associated with high risk of recurrence and poor prognosis in colorectal cancer (12) . In the present study, serum levels of CA19-9 were concerned with hematogenous metastases, especially liver metastases, the degree of lymph node metastases, the frequency of recurrence after curative surgery and overall prognosis. Some authors have shown a significant association between high pre-operative levels of CA19-9 and poor prognosis, even when pre-operative factors including clinical stage, serum levels of CEA and CA19-9 were compared by multivariate analysis (5, 7, 11) . CA19-9 is thought to be predictive of prognosis, however, none of these studies has demonstrated any advantage of CA19-9 over clinical stage.
In the present study, low serum concentration of E-selectin was defined as ,50 U/ml in healthy volunteers, and on that basis, 20.4% of all patients belonged to the high E-selectin group. The positive rate of E-selectin in the present study was similar to that reported in the previous studies on colorectal cancer (29, 30) . Previous studies have revealed that patients with Dukes' D colorectal cancer have significantly higher serum levels of E-selectin than those with Dukes' A, B and C cancer (31, 32) . Many previous studies have also documented a high serum level of E-selectin in colorectal cancer with metastatic disease, and Table 2 . Sites of metastases according to serum levels of CA19-9 and E-selectin Table 3 . Frequencies of curative surgery, recurrence rates and recurrence sites after curative surgery according to serum levels of CA19-9 or E-selectin 
distinctively high levels in cases with liver metastases (8,26,32 -34) . In the present study, liver metastases were found with a significantly higher frequency in the high than in the low E-selectin group. However, there was no significant difference in the frequency of Dukes' D colorectal cancer between the high and low E-selectin group, in spite of a greater number of patients with liver metastases in the high E-selectin group compared with that in the low E-selectin group. In comparison with previous studies, the results of the present study seem to be partially contradictory Pre-operative serum level of E-selectin may not be useful in predicting recurrence after surgery, however, it could be useful to check serum levels of E-selectin regularly after surgery as a marker for follow-up of patients. The present study showed that Dukes' D cancer, especially with liver metastases, was found significantly more often in patients with high serum levels of E-selectin and CA19-9 (group IV) than in patients with other levels of E-selectin and CA19-9. Our findings suggest that E-selectin and CA19-9 are associated with the process of hematogenous metastasis from colorectal cancer. Hematogenous metastasis is the most important factor for the survival of patients with colorectal cancer. As a result of higher rate of Dukes' D cancer, curative surgery was performed significantly less and prognosis was significantly worse in group IV than group II, which also belongs to the high CA19-9 group. Furthermore, there were no significant differences in the frequencies of curative surgery and prognosis between group II and the low CA19-9 groups (groups I and III). Even if the serum level of CA19-9 was high, prognosis was not poor in patients with a low serum level of E-selectin. Prognosis categorized by serum levels of CA19-9 and E-selectin was also analysed with adjusting the Dukes stage (data not shown). However, significant differences were not found in prognosis in each Dukes stage. This result may be due to the small number of tested patients. Although the present study did not show the results of molecular levels, we did show that it was useful for prediction of prognosis to measure serum levels of E-selectin and CA19-9 before surgery. Cimetidine has been shown to improve the survival of patients with colorectal cancer, whose mechanism of effectiveness is understood based on the interaction of CA19-9 and E-selectin (35 -37) . In vitro experiments showed that the interaction of CA19-9 with E-selectin is involved in initiating hematogenous metastases in colorectal cancer (26, 27) . Kobayashi has demonstrated that cimetidine Frequencies of Dukes' D cancer were compared between two groups, in which probability value was 0.014 for groups IV and II, 0.20 for groups I and II, 0.16 for groups II and III. Figure 1 . Prognosis of patients according to serum level of CA19-9 or E-selectin. Note that prognosis was significantly better in the normal than the high CA19-9 group, whereas there was no significant difference in prognosis between the high and low E-selectin groups. Frequency of liver metastasis was compared between two groups, in which probability value was 0.002 for groups IV and II, 0.001 for groups IV and I, 0.002 for groups IV and III, 0.49 for groups I and II, 0.60 for groups II and III and 0.70 for groups I and III.
can block the adhesion of a colorectal tumor cell line to an endothelial cell monolayer in cell culture, and that it can suppress tumor cell metastasis in a nude mouse model (38) .
In conclusion, our results suggest that it was useful to measure both CA19-9 and E-selectin as markers of hematogenous metastases and as predictors of prognosis in colorectal cancer. It will be necessary to study a larger series of patients with colorectal cancer to provide more information regarding the usefulness of serum E-selectin. Figure 2 . Prognosis of patients classified as groups I -IV according to the serum levels of E-selectin and CA19-9. Note that prognosis was significantly poorer in group IV than group II (P ¼ 0.02), which also belongs to the high CA19-9 group (Fig. 2B) , whereas there was no significant difference in prognosis between group I and group III, which belongs to the low CA19-9 group (Fig. 2A) . Frequencies of curative surgery were compared between two groups, in which probability value was 0.01 for groups IV and II, 0.49 for groups I and II and 0.60 for groups II and III. There were no significant differences between two groups (groups IV and II, groups I and II and groups II and III) in the recurrence rates and recurrence sites.
